Jozef Madzo to Antineoplastic Agents
This is a "connection" page, showing publications Jozef Madzo has written about Antineoplastic Agents.
Connection Strength
0.191
-
A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy. Clin Cancer Res. 2023 06 01; 29(11):2052-2065.
Score: 0.102
-
Transcriptional Selectivity of Epigenetic Therapy in Cancer. Cancer Res. 2017 01 15; 77(2):470-481.
Score: 0.065
-
Slower molecular response to treatment predicts poor outcome in patients with TEL/AML1 positive acute lymphoblastic leukemia: prospective real-time quantitative reverse transcriptase-polymerase chain reaction study. Cancer. 2003 Jan 01; 97(1):105-13.
Score: 0.025